New drug aims to shrink fatty liver in diabetes patients
NCT ID NCT07198516
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 34 times
Summary
This study tests whether a drug called Henggliejin can improve fatty liver in people who have both type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). About 149 adults will take the drug for 48 weeks, and doctors will check liver health using a simple blood test called FIB-4. The goal is to see if the drug is safe and helps reduce liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.